<DOC>
	<DOC>NCT01967732</DOC>
	<brief_summary>The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile (rate and amount of nicotine absorbed) following a single use of the THS 2.2 compared to the PK profiles from a single use of a conventional cigarette (CC) and from a single use of nicotine nasal spray (NNS).</brief_summary>
	<brief_title>Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)</brief_title>
	<detailed_description />
	<mesh_term>Nicotine</mesh_term>
	<criteria>Subject is Caucasian Smoking, healthy subject as judged by the Investigator. Subject has smoked at least 10 commercially available non menthol CCs per day (no brand restrictions) for the last 4 weeks. Subject has smoked for at least the last 3 consecutive years. Subject does not plan to quit smoking in the next 3 months. As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason). Subject has received medication within 14 days or within 5 halflives of a drug (whichever is longer) which has an impact on CYP2A6 activity. Female subject is pregnant or breast feeding. Female subject does not agree to use an acceptable method of effective contraception.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Smoking</keyword>
	<keyword>Nicotine absorption</keyword>
	<keyword>Modified risk tobacco product</keyword>
	<keyword>Conventional cigarette</keyword>
	<keyword>Nicotine replacement therapy</keyword>
	<keyword>Nicotine nasal spray</keyword>
</DOC>